Bradykinin B1-receptor antagonists of formula
##STR1##
are disclosed. The compounds are useful for treating diseases associated with
inappropriate bradykinin receptor activity, such as diabetic vasculopathy, inflammation,
pain, hyperalgesia, asthma, rhinitis, septic shock, atherosclerosis and multiple
sclerosis. Pyrimidines, triazines, and anilines in which Q is imidazolyl or pyrrolyl
are particularly preferred.
